PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Hexaminolevulinate→

Hexaminolevulinate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
140898-97-1
Molecular formula
C11H21NO3
Molecular weight
215.29 g/mol
Drug class
Hexaminolevulinate hydrochlorideprodrug of 5-aminolevulinic acid for photodynamic diagnostic imaging
Mechanism of action
Converted intracellularly to porphyrin precursors, including fluorescent protoporphyrin IX, which accumulates preferentially in urothelial lesions. Under blue-light cystoscopy, fluorescent tissue is detected to aid visualisation of bladder lesions.
Indications / reported uses
  • Optical imaging of bladder cancer during blue-light cystoscopy in adults with known or suspected non-muscle-invasive bladder cancer, as an adjunct to white-light cystoscopy; not a stand-alone diagnostic test

Sources: US DailyMed — Cysview (hexaminolevulinate) · NLM MeSH — Hexaminolevulinate · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Hexaminolevulinate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Hexaminolevulinate Permitted Daily Exposure (PDE) report (the Hexaminolevulinate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Hexaminolevulinate Occupational Exposure Limit (OEL) report (the Hexaminolevulinate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.